Jake, why is the disposition of the 3 targeted BOD members a factor in your analysis? I recognize the BOD compensation and Delaware Chancellery Court decision issues. Yet, tech value is what it is, unless the underlying theme here is how the three BOD members may have said "no" to a deal offered by a Pharma and Ronin taking the reins is viewed as giving the deal back to Pharma on their terms. That being the case, tech value being realized in the share price is not really being accomplished, it seems.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
AI
